Printer Friendly Version
Printer Friendly Version
Printer Friendly Version
L.6.01.405
Magnetic resonance imaging (MRI) is a multiplanar imaging method based on an interaction between radiofrequency (RF) electromagnetic fields and certain nuclei in the body (usually hydrogen nuclei) after the body has been placed in a strong magnetic field. MRI differentiates between normal and abnormal tissues, providing a sensitive examination to detect disease. This sensitivity is based on the high degree of inherent contrast due to variations in the magnetic relaxation properties of different tissues, both normal and diseased, and the dependence of the MRI signal on these tissue properties.
MRI is a radiology technique that uses magnetism, radio waves, and a computer to produce images of body structures. The MRI scanner is a tube surrounded by a giant circular magnet. The patient is placed on a moveable bed that is inserted into the magnet. The magnet creates a strong magnetic field that aligns the protons of hydrogen atoms, which are then exposed to a beam of radio waves. This spins the various protons of the body, and they produce a faint signal that is detected by the receiver portion of the MRI scanner. The receiver information is processed by a computer, and an image is produced. The image and resolution produced by MRI is quite detailed and can detect tiny changes of structures within the body. For some procedures, contrast agents, such as gadolinium, are used to increase the accuracy of the images.
MRI is a proven imaging modality for the detection, evaluation, assessment, staging, and follow-up of disorders of the abdomen. Properly performed and interpreted, MRI not only contributes to diagnosis but also can guide treatment planning, help predict outcome, and increase diagnostic confidence. However, MRI should be performed only for a valid medical reason, and only after careful consideration of alternative imaging modalities. The strengths of MRI and other modalities should be weighed as to their suitability in particular patients and in particular clinical conditions.
The choice of MRI of the abdomen requires an analysis of the strengths of MRI as well as its suitability for the particular patient and particular clinical situation. For suspected lesions requiring a technique to detect subtle soft-tissue contrast (lesion characterization), to provide a three-dimensional depiction of a lesion, and to image other than with ionizing radiation or in a patient with an allergy to iodinated contrast and a need for intravenous contrast enhancement, MRI might be the procedure of choice provided that the patient does not have a contraindication to MRI.
MRI of the pelvis is a proven and useful tool for the evaluation, assessment of severity, and follow-up of diseases of the male and female pelvic organs. It should be performed only for a valid medical reason. MRI of the pelvis is the imaging modality of choice for many clinical situations involving pelvic pathology. This technique has superb soft-tissue contrast, particularly of the gynecologic organs, and has the advantage of providing multiplanar and three-dimensional (3D) depiction of anatomy and pathology. Additional benefits include absence of ionizing radiation and exposure to iodinated contrast material.
Related medical policies are -
Provider Accreditation for MRI – Network Providers
All Network Providers billing the technical component of the MRI must be accredited in MRI by the Intersocietal Accreditation Commission (IAC) or a MRI module by the American College of Radiology (ACR) or RadSite. The professional component of the MRI will be reimbursed based upon the accreditation of the facility as the ACR, IAC or RadSite facility accreditations require that interpreting professional physicians also be accredited.
MRI of the Abdomen
Magnetic resonance imaging (MRI) of the abdomen is considered medically necessary for the following indications:
Evaluation of suspicious known mass/tumors (unconfirmed diagnosis of cancer):
Initial evaluation of suspicious abdomen masses/tumors found only in the abdomen by physical exam or imaging study
Surveillance: One follow-up exam to ensure no suspicious change has occurred in a tumor in the abdomen. No further surveillance unless tumor(s) are specified as highly suspicious, or change was found on last follow-up. Surveillance may be prolonged beyond one year if recommended and an indolent tumor or neoplasm is suspected.
Evaluation of known cancer:
Evaluation of known or suspected abdominal metastases
Known cancer with suspected abdomen metastasis based on a sign, symptom or abnormal lab value
Surveillance after known cancer: Once per year. Last test must be over ten (10) months ago before new approval for surveillance of known cancer
Evaluation of suspected or known vascular disease (e.g., hematomas, evaluation of abdominal aortic aneurysm)
For location or evaluation of undescended testes in adults and in children, including determination of location of testes, where ultrasound has been done previously
To provide an alternative to abdominal CT when CT would be limited due to allergy to radiographic contrast material
To provide an alternative to follow-up of an indeterminate abdomen CT when previous CT/Ultrasound was equivocal and needed to clarify a finding a CT could not
Suspected adrenal mass or pheochromocytoma based on diagnostic testing/imaging results, and/or a suspicious clinical presentation
Evaluation of known Crohn’s disease when active inflammation is suspected
To evaluate an acute abdomen in a <20 week pregnancy when other diagnostic studies (ultrasound) are inconclusive
To evaluate for vascular patency
To characterize liver lesions, suspected pancreatic lesions not seen on CT, cirrhosis, and status of liver for donation
Magnetic resonance cholangiopancreatography (MRCP) for suspected hepatobiliary disease
To evaluate solid organ mass in the abdomen when CT is inconclusive
Evaluation of fetus when fetal or placental abnormalities are known or suspected and Ultrasound is inconclusive
Pre or post organ transplantation of the the liver, kidney, or pancreas
Further evaluation of pancreatic masses detected on CT or US when recommended in the Radiology report
MRI of the Pelvis
Magnetic resonance imaging (MRI) of the pelvis is considered medically necessary for the following indications:
Evaluation of suspicious/known mass/tumors (unconfirmed diagnosis of cancer) for further evaluation of indeterminate or questionable findings, identified on more standard imaging exams such as ultrasound (US) and/or CT:
Initial evaluation of suspicious pelvic masses/tumors found only in the pelvis by physical exam or imaging study
Surveillance: One follow-up exam to ensure no suspicious change has occurred in a tumor in the pelvic. No further surveillance unless tumor(s) are specified as highly suspicious, or change was found on last follow-up.
Evaluation of known cancer for further evaluation of indeterminate or questionable findings identified on more standard imaging exams such as ultrasound (US) and computed tomography (CT):
Initial staging of known cancer:
All cancers, excluding the following:
Excluding Basal Cell Carcinoma of the skin,
Excluding Melanoma without symptoms or signs of metastasis.
Three (3) month follow-up of known abdomen/pelvic cancer undergoing active treatment within the past year.
Six (6) month follow-up of known abdominal/pelvic cancer undergoing active treatment within the past year.
Follow-up of known cancer of patient undergoing active treatment within the past year.
Known cancer with suspected abdominal/pelvic metastasis based on a sign, symptom or an abnormal lab value.
Surveillance after known cancer: Once per year last test must be over ten (10) months ago before new approval for surveillance of known cancer.
Evaluation of suspected or known vascular disease (e.g., hematomas, evaluation of abdominal aortic aneurysm)
For location or evaluation of undescended testes in adults and in children, including determination of location of testes, where ultrasound has been done previously. Meets criteria and provides an alternative to pelvic CT when CT would be limited due to allergy to radiographic contrast material.
To provide an alternative to follow-up of an indeterminate pelvic CT when previous CT/ultrasound was equivocal and needed to clarify a finding a CT could not.
For evaluation and characterization of uterine and adnexal masses, (e.g., fibroids, ovaries, tubes and uterine ligaments), where ultrasound has been done previously.
For evaluation of uterus prior to embolization.
For evaluation of endometriosis.
Prior to uterine surgery if there is abnormality suspected on prior US (e.g., spinal bifida).
For evaluation of known or suspected aseptic/avascular necrosis of hip(s).
For evaluation of known or suspected abnormality of the fetus noted on prior imaging and no prior pelvis MRI.
For known or suspected prostate cancer for recurrence workup:
Initial treatment by radical prostatectomy:
Failure of PSA to fall to undetectable levels or PSA detectable and rising on at least 2 subsequent determinations
Initial treatment radiation therapy (RT):
Post-RT rising PSA or positive digital exam and is candidate for local therapy
Evaluate for occult fracture of hip and/or pelvis
Pre-operative planning for pelvic floor repair
Evaluation of urethral diverticulum and periurethral cysts in females
Evaluation of the uterus prior to or after embolization procedure
Investigation of postmenopausal bleeding when Ultrasound is inconclusive
Evaluation of known or suspected Mullerian duct developmental abnormalities
Evaluation for organ of origin of a previously documented mass in the male or female pelvis
Investigation of lack or menses by age 15 in female patient
Evaluation of labral pathology in the hip with or without prior arthrogram
Evaluation of the painful hip with normal or equivocal x-rays
Evaluation of painful hip post metal on metal prosthesis
Magnetic resonance imaging (MRI) of the abdomen and pelvis is considered not medically necessary for all other indications, including when performed for screening purposes in asymptomatic patients (absence of signs, symptoms, or disease).
State Health Plan (SHP) Members:For dates of service on or prior to 12/31/2015, this policy applies to MRI of the abdomen and pelvis when performed in the emergency room. This policy does not apply to MRI of the abdomen and pelvis performed in non-emergency room settings. MRI of the abdomen and pelvis performed in non-emergency room settings require pre-certification by the Plan’s Utilization Review Vendor.
Effective 01/01/2016, this policy applies to MRI of the abdomen and pelvis performed in all settings for State Health Plan Members.
The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.
Reimbursement for MRI imaging of the same anatomical area is generally limited to one (1) MRI imaging within a 6-month period. MRI imaging in excess of one (1) within a 6-month period will be subject to medical necessity review. Documentation should include radiology reason for study, radiology comparison study-date and time, radiology comparison study observation, radiology impression, and radiology study recommendation.
Additional MRI imaging of the same anatomical area may be appropriate for the following, including, but not limited to: diagnosis, staging or follow-up of cancer, follow-up assessment during or after therapy for known metastases, follow-up of member who have had an operative, interventional or therapeutic procedure (e.g., surgery, embolization), reevaluation due to change in clinical status (e.g., deterioration), new or worsening clinical findings, (e.g., neurologic signs, symptoms), medical intervention which warrants reassessment, reevaluation for treatment planning, follow-up during and after completion of therapy or treatment to assess effectiveness, and evaluation after intervention or surgery.
Re-imaging or additional imaging due to poor contrast enhanced exam or technically limited exam is the responsibility of the imaging provider.
Medically Necessary is defined as those services, treatments, procedures, equipment, drugs, devices, items or supplies furnished by a covered Provider that are required to identify or treat a Member's illness, injury or Mental Health Disorders, and which Company determines are covered under this Benefit Plan based on the criteria as follows in A through D:
A. consistent with the symptoms or diagnosis and treatment of the Member's condition, illness, or injury; and
B. appropriate with regard to standards of good medical practice; and
C. not solely for the convenience of the Member, his or her Provider; and
D. the most appropriate supply or level of care which can safely be provided to Member. When applied to the care of an Inpatient, it further means that services for the Member's medical symptoms or conditions require that the services cannot be safely provided to the Member as an Outpatient.
For the definition of medical necessity, “standards of good medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. BCBSMS makes no payment for services, treatments, procedures, equipment, drugs, devices, items or supplies which are not documented to be Medically Necessary. The fact that a Physician or other Provider has prescribed, ordered, recommended, or approved a service or supply does not in itself, make it Medically Necessary.
Investigative is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized as a generally accepted standard of good medical practice for the treatment of the condition being treated and; therefore, is not considered medically necessary. For the definition of Investigative, “generally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting.
05/19/2014: New policy added. Approved by Radiology Physician Advisory Committee and Medical Policy Advisory Committee. Effective 07/15/2014.
06/30/2014: Policy Exceptions section updated regarding SHP members to state that this policy applies to MRI of the abdomen and pelvis when performed in the emergency room. This policy does not apply to MRI of the abdomen and pelvis performed in non-emergency room settings. MRI of the abdomen and pelvis performed in non-emergency room settings require pre-certification by the Plan’s Utilization Review Vendor.
07/22/2014: Added ICD-9 code 593.9 to the Code Reference section.
09/01/2015: Medical policy revised to add ICD-10 codes. Code Reference section updated to correct ICD-9 diagnosis code ranges 183.0 – 183.8 and 211.1 – 211.9. Correct ranges are 183.0 – 183.9 and 211.0 – 211.9.
12/31/2015: Policy guidelines updated to add medically necessary and investigative definitions. Code Reference section updated to add new 2016 CPT codes 74712 and 74713. Policy Exceptions section updated regarding SHP members to state that effective 01/01/2016, this policy applies to MRI of the abdomen and pelvis performed in all settings for State Health Plan Members.
02/09/2016: Code Reference section updated to correct the following ICD-10 diagnosis code: 49.6 should be C49.6.
02/17/2016: Code Reference section updated to correct the following ICD-10 diagnosis code range: S37.20X - S37.29X should be S37.20XA - S37.29XS.
06/08/2016: Policy number L.6.01.405 added.
09/30/2016: Code Reference section updated to add the following ICD-10 diagnosis codes: C49.A0 - C49.A9, D49.512, D49.519, D49.59, I72.5, I72.6, K85.00 - K85.92, R97.20, R97.21, R93.41, R93.421, R93.422, R93.429, R93.49, Z98.890, and Z98.891. Revised the following ICD-10 diagnosis code descriptions: C7A.094, C7A.095, C7A.096, D3A.094, D3A.095, D3A.096, and P00.89.
05/18/2018: Medical policy links updated in policy description. Removed deleted ICD-10 diagnosis codes D49.5, R93.4, R97.2, and Z98.89.
09/28/2018: Code Reference section updated to add new ICD-10 diagnosis codes R93.813, R93.819, and R93.89, effective 10/01/2018.
11/02/2018: Code Reference section updated to add new ICD-10 diagnosis codes R93.811 and R93.812.
09/29/2020: Code Reference section updated to add new ICD-10 diagnosis codes K74.00, K74.01, and K74.02, effective 10/01/2020. Removed deleted ICD-10 diagnosis code R93.8.
10/01/2021: Code Reference section updated to add new ICD-10 diagnosis code C79.63, effective 10/01/2021.
09/27/2022: Policy Guidelines updated to change "Nervous/Mental Conditions" to "Mental Health Disorders" and "Medically Necessary" to "medical necessity." Code Reference section updated to add new ICD-10 diagnosis codes I71.30, I71.31, I71.32, I71.33, I71.40, I71.41, I71.42, I71.43, I71.50, I71.51, I71.52, I71.60, I71.61, I71.62, N80.00, N80.01, N80.02, N80.03, N80.101, N80.102, N80.103, N80.109, N80.111, N80.112, N80.113, N80.119, N80.121, N80.122, N80.123, N80.129, N80.201, N80.202, N80.203, N80.209, N80.211, N80.212, N80.213, N80.219, N80.221, N80.222, N80.223, N80.229, N80.30, N80.311, N80.312, N80.319, N80.321, N80.322, N80.329, N80.331, N80.332, N80.333, N80.339, N80.341, N80.342, N80.343, N80.349, N80.351, N80.352, N80.353, N80.359, N80.361, N80.362, N80.363, N80.369, N80.371, N80.372, N80.373, N80.379, N80.381, N80.382, N80.383, N80.389, N80.391, N80.392, N80.399, N80.3A1, N80.3A2, N80.3A3, N80.3A9, N80.3B1, N80.3B2, N80.3B3, N80.3B9, N80.3C1, N80.3C2, N80.3C3, N80.3C9, N80.40, N80.41, N80.42, N80.50, N80.511, N80.512, N80.519, N80.521, N80.522, N80.529, N80.531, N80.532, N80.539, N80.541, N80.542, N80.549, N80.551, N80.552, N80.559, N80.561, N80.562, N80.569, N80.A0, N80.A1, N80.A2, N80.A41, N80.A42, N80.A43, N80.A49, N80.A51, N80.A52, N80.A53, N80.A59, N80.A61, N80.A62, N80.A63, N80.A69, N80.B1, N80.B2, N80.B31, N80.B32, N80.B39, N80.B4, N80.B5, N80.B6, N80.C0, N80.C10, N80.C11, N80.C19, N80.C2, N80.C3, N80.C4, N80.C9, N80.D0, N80.D1, N80.D2, N80.D3, N80.D4, N80.D5, N80.D6, N80.D9, O35.AXX0, O35.AXX1, O35.AXX2, O35.AXX3, O35.AXX4, O35.AXX5, O35.AXX9, O35.BXX0, O35.BXX1, O35.BXX2, O35.BXX3, O35.BXX4, O35.BXX5, O35.BXX9, O35.CXX0, O35.CXX1, O35.CXX2, O35.CXX3, O35.CXX4, O35.CXX5, O35.CXX9, O35.DXX0, O35.DXX1, O35.DXX2, O35.DXX3, O35.DXX4, O35.DXX5, O35.DXX9, O35.EXX0, O35.EXX1, O35.EXX2, O35.EXX3, O35.EXX4, O35.EXX5, O35.EXX9, O35.FXX0, O35.FXX1, O35.FXX2, O35.FXX3, O35.FXX4, O35.FXX5, O35.FXX9, O35.GXX0, O35.GXX1, O35.GXX2, O35.GXX3, O35.GXX4, O35.GXX5, O35.GXX9, O35.HXX0, O35.HXX1, O35.HXX2, O35.HXX3, O35.HXX4, O35.HXX5, and O35.HXX9, effective 10/01/2022.
11/08/2022: Policy reviewed; no changes.
09/27/2023: Code Reference section updated to add new ICD-10 diagnosis codes D13.91, D13.99, D48.113, D48.114, M80.0B1A, M80.0B1D, M80.0B1G, M80.0B1K, M80.0B1P, M80.0B1S, M80.0B2A, M80.0B2D, M80.0B2G, M80.0B2K, M80.0B2P, M80.0B2S, M80.0B9A, M80.0B9D, M80.0B9G, M80.0B9K, M80.0B9P, M80.0B9S, M80.8B1A, M80.8B1D, M80.8B1G, M80.8B1K, M80.8B1P, M80.8B1S, M80.8B2A, M80.8B2D, M80.8B2G, M80.8B2K, M80.8B2P, M80.8B2S, M80.8B9A, M80.8B9D, M80.8B9G, M80.8B9K, M80.8B9P, M80.8B9S, Q44.70, Q44.71, and Q44.79. Revised the code description for ICD-10 diagnosis codes I71.51, I71.52, I71.61, and I71.62. Effective 10/01/2023.
12/04/2023: Policy reviewed. Policy statements unchanged. Code Reference section updated to remove deleted ICD-10 diagnosis codes I71.3, I71.4, I71.5, I71.6, N80.0, N80.1, N80.2, N80.3, N80.4, and N80.5.
12/01/2024: Code Reference section updated to add ICD-10 diagnosis codes K76.9, N28.89, Q61.2, and R16.0. Removed deleted ICD-10 diagnosis codes D13.9 and Q44.7.
12/06/2024: Policy reviewed; no changes.
10/01/2025: Code Reference section updated to add new ICD-10 diagnosis codes R10.85, R10.8A1, R10.8A2, R10.8A3, R10.8A9, R10.A0, R10.A1, R10.A2, and R10.A3.
11/01/2025: Added RadSite as an imaging accreditation body.
American College of Radiology. ACR Practice Guideline for Performing and Interpreting Magnetic Resonance Imaging (MRI), 2011.
American College of Radiology. ACR Practice Guideline for the Performance of Magnetic Resonance Imaging (MRI) of the Abdomen (Excluding the Liver), 2010.
American College of Radiology. ACR Practice Guideline for the Performance of Magnetic Resonance Imaging (MRI) of the Soft-Tissue Components of the Pelvis, 2010.
Magnetic Resonance Imaging (MRI) Abdomen and Pelvis medical policy, Blue Cross and Blue Shield of Florida
Medical Policy Advisory Committee
Radiology Physician Advisory Committee
This may not be a comprehensive list of procedure codes applicable to this policy.
Code Number | Description | ||
CPT-4 | |||
72195 | Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s) | ||
72196 | Magnetic resonance (eg, proton) imaging, pelvis; with contrast material(s) | ||
72197 | Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences | ||
74181 | Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s) | ||
74182 | Magnetic resonance (eg, proton) imaging, abdomen; with contrast material(s) | ||
74183 | Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences | ||
74712 | Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; single or first gestation | ||
74713 | Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; each additional gestation (List separately in addition to code for primary procedure) | ||
HCPCS | |||
ICD-9 Procedure | ICD-10 Procedure | ||
ICD-9 Diagnosis | ICD-10 Diagnosis | ||
151.0 - 151.9 | Malignant neoplasm of stomach | C16.0 - C16.9 | Malignant neoplasm of stomach |
152.0 - 152.9 | Malignant neoplasm of small intestine, including duodenum | C17.0 - C17.9 | Malignant neoplasm of small intestine |
153.0 - 153.9 | Malignant neoplasm of colon | C18.0 - C18.9 | Malignant neoplasm of colon |
154.0 - 154.8 | Malignant neoplasm of rectum, rectosigmoid junction, and anus | C19 | Malignant neoplasm of rectosigmoid junction |
C20 | Malignant neoplasm of rectum | ||
C21.0 - C21.8 | Malignant neoplasm of anus and anal canal | ||
155.0 - 155.2 | Malignant neoplasm of liver and intrahepatic bile ducts | C22.0 - C22.9 | Malignant neoplasm of liver and intrahepatic bile ducts |
156.0 - 156.9 | Malignant neoplasm of gallbladder and extrahepatic bile ducts | C23 C24.0 - C24.9 | Malignant neoplasm of gallbladder Malignant neoplasm of other and unspecified parts of biliary tract |
157.0 - 157.9 | Malignant neoplasm of pancreas | C25.0 - C25.9 | Malignant neoplasm of pancreas |
158.0 - 158.9 | Malignant neoplasm of retroperitoneum and peritoneum | C45.1 C48.0 - C48.8 | Mesothelioma of peritoneum Malignant neoplasm of retroperitoneum and peritoneum |
159.0 - 159.9 | Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum | C26.0 - C26.9 | Malignant neoplasm of other and ill-defined digestive organs |
170.6 | Malignant neoplasm of pelvic bones, sacrum, and coccyx | C41.4 | Malignant neoplasm of pelvic bones, sacrum and coccyx |
170.9 | Malignant neoplasm of bone and articular cartilage, site unspecified | C40.80 - C40.82 C40.90 - C40.92 | Malignant neoplasm of overlapping sites of bone and articular cartilage of limb Malignant neoplasm of unspecified bones and articular cartilage of limb |
C49.A0 - C49.A9 | Gastrointestinal stromal tumor | ||
171.5 | Malignant neoplasm of connective and other soft tissue of abdomen | C47.4 C49.4 | Malignant neoplasm of peripheral nerves of abdomen Malignant neoplasm of connective and soft tissue of abdomen |
171.6 | Malignant neoplasm of connective and other soft tissue of pelvis | C47.5 C49.5 | Malignant neoplasm of peripheral nerves of pelvis Malignant neoplasm of connective and soft tissue of pelvis |
171.7 | Malignant neoplasm of connective and other soft tissue of trunk, unspecified site | C49.6 | Malignant neoplasm of connective and soft tissue of trunk, unspecified |
171.8 | Malignant neoplasm of other specified sites of connective and other soft tissue | C47.8 C49.8 | Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system Malignant neoplasm of overlapping sites of connective and soft tissue |
171.9 | Malignant neoplasm of connective and other soft tissue, site unspecified | C49.9 | Malignant neoplasm of connective and soft tissue, unspecified |
176.1 | Kaposi's sarcoma of soft tissue | C46.1 | Kaposi's sarcoma of soft tissue |
176.3 | Kaposi's sarcoma of gastrointestinal sites | C46.4 | Kaposi's sarcoma of gastrointestinal sites |
176.8 | Kaposi's sarcoma of other specified sites | C46.7 | Kaposi's sarcoma of other sites |
176.9 | Kaposi's sarcoma of unspecified site | C46.9 | Kaposi's sarcoma, unspecified |
179.0 | Malignant neoplasm of uterus, part unspecified | C55 | Malignant neoplasm of uterus, part unspecified |
180.0 - 180.9 | Malignant neoplasm of cervix uteri | C53.0 - C53.9 | Malignant neoplasm of cervix uteri |
182.0 - 182.8 | Malignant neoplasm of body of uterus | C54.0 - C54.9 | Malignant neoplasm of corpus uteri |
183.0 - 183.9 | Malignant neoplasm of ovary and other uterine adnexa | C56.1 - C56.9 | Malignant neoplasm of ovary |
C57.00 - C57.02 | Malignant neoplasm of fallopian tube | ||
C57.10 - C57.12 | Malignant neoplasm of broad ligament | ||
C57.20 - C57.22 | Malignant neoplasm of round ligament | ||
C57.3 | Malignant neoplasm of parametrium | ||
C57.4 | Malignant neoplasm of uterine adnexa, unspecified | ||
184.4 | Malignant neoplasm of vulva, unspecified site | C51.9 | Malignant neoplasm of vulva, unspecified |
185 | Malignant neoplasm of prostate | C61 | Malignant neoplasm of prostate |
186.0 | Malignant neoplasm of undescended testis | C62.00 - C62.02 | Malignant neoplasm of undescended testis |
186.9 | Malignant neoplasm of other and unspecified testis | C62.10 - C62.12 C62.90 - C62.92 | Malignant neoplasm of descended testis Malignant neoplasm of testis, unspecified whether descended or undescended |
187.1 - 187.9 | Malignant neoplasm of penis and other male genital organs | C60.0 - C60.9 C63.00 - C63.9 | Malignant neoplasm of penis Malignant neoplasm of other and unspecified male genital organs |
188.0 - 188.9 | Malignant neoplasm of bladder | C67.0 - C67.9 | Malignant neoplasm of bladder |
189.0 | Malignant neoplasm of kidney, except pelvis | C64.1 - C64.9 | Malignant neoplasm of kidney, except renal pelvis |
189.1 | Malignant neoplasm of renal pelvis | C65.1 - C65.9 | Malignant neoplasm of renal pelvis |
189.2 | Malignant neoplasm of ureter | C66.1 - C66.9 | Malignant neoplasm of ureter |
189.3 | Malignant neoplasm of urethra | C68.0 | Malignant neoplasm of urethra |
194.0 | Malignant neoplasm of adrenal gland | C74.00 - C74.92 | Malignant neoplasm of adrenal gland |
195.2 | Malignant neoplasm of abdomen | C76.2 | Malignant neoplasm of abdomen |
195.3 | Malignant neoplasm of pelvis | C76.3 | Malignant neoplasm of pelvis |
196.2 | Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes | C77.2 | Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes |
196.6 | Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes | C77.5 | Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes |
197.4 | Secondary malignant neoplasm of small intestine including duodenum | C78.4 | Secondary malignant neoplasm of small intestine |
197.5 | Secondary malignant neoplasm of large intestine and rectum | C78.5 | Secondary malignant neoplasm of large intestine and rectum |
197.6 | Secondary malignant neoplasm of retroperitoneum and peritoneum | C78.6 | Secondary malignant neoplasm of retroperitoneum and peritoneum |
197.7 | Secondary malignant neoplasm of liver | C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct |
197.8 | Secondary malignant neoplasm of other digestive organs and spleen | C78.7 C78.80 - C78.89 | Secondary malignant neoplasm of liver and intrahepatic bile duct Secondary malignant neoplasm of other and unspecified digestive organs |
198.0 | Secondary malignant neoplasm of kidney | C79.00 - C79.02 | Secondary malignant neoplasm of kidney and renal pelvis |
198.1 | Secondary malignant neoplasm of other urinary organs | C79.10 - C79.19 | Secondary malignant neoplasm of bladder and other and unspecified urinary organs |
198.6 | Secondary malignant neoplasm of ovary | C79.60 - C79.63 | Secondary malignant neoplasm of ovary |
198.7 | Secondary malignant neoplasm of adrenal gland | C79.70 - C79.72 | Secondary malignant neoplasm of adrenal gland |
198.82 | Secondary malignant neoplasm of genital organs | C79.82 | Secondary malignant neoplasm of genital organs |
209.00 - 209.03 | Malignant carcinoid tumors of the small intestine | C7A.010 - C7A.019 | Malignant carcinoid tumors of the small intestine |
209.10 - 209.17 | Malignant carcinoid tumors of the appendix, large intestine, and rectum | C7A.020 - C7A.029 | Malignant carcinoid tumors of the appendix, large intestine, and rectum |
209.20 | Malignant carcinoid tumor of unknown primary site | C7A.00 | Malignant carcinoid tumor of unspecified site |
209.23 | Malignant carcinoid tumor of the stomach | C7A.092 | Malignant carcinoid tumor of the stomach |
209.24 | Malignant carcinoid tumor of the kidney | C7A.093 | Malignant carcinoid tumor of the kidney |
209.25 | Malignant carcinoid tumor of foregut, not otherwise specified | C7A.094 | Malignant carcinoid tumor of the foregut, unspecified |
209.26 | Malignant carcinoid tumor of midgut, not otherwise specified | C7A.095 | Malignant carcinoid tumor of the midgut, unspecified |
209.27 | Malignant carcinoid tumor of hindgut, not otherwise specified | C7A.096 | Malignant carcinoid tumor of the hindgut, unspecified |
209.29 | Malignant carcinoid tumor of other sites | C7A.098 | Malignant carcinoid tumors of other sites |
209.30 | Malignant poorly differentiated neuroendocrine carcinoma, any site | C7A.1 C7A.8 | Malignant poorly differentiated neuroendocrine tumors Other malignant neuroendocrine tumors |
209.40 - 209.43 | Benign carcinoid tumors of the small intestine | D3A.010 - D3A.019 | Benign carcinoid tumors of the small intestine |
209.50 - 209.57 | Benign carcinoid tumors of the appendix, large intestine, and rectum | D3A.020 - D3A.029 | Benign carcinoid tumors of the appendix, large intestine, and rectum |
209.63 | Benign carcinoid tumor of the stomach | D3A.092 | Benign carcinoid tumor of the stomach |
209.64 | Benign carcinoid tumor of the kidney | D3A.093 | Benign carcinoid tumor of the kidney |
209.65 | Benign carcinoid tumor of foregut, not otherwise specified | D3A.094 | Benign carcinoid tumor of the foregut, unspecified |
209.66 | Benign carcinoid tumor of midgut, not otherwise specified | D3A.095 | Benign carcinoid tumor of the midgut, unspecified |
209.67 | Benign carcinoid tumor of hindgut, not otherwise specified | D3A.096 | Benign carcinoid tumor of the hindgut, unspecified |
209.69 | Benign carcinoid tumor of other sites | D3A.098 | Benign carcinoid tumors of other sites |
209.70 | Secondary neuroendocrine tumor, unspecified site | C7B.00 | Secondary carcinoid tumors, unspecified site |
209.72 | Secondary neuroendocrine tumor of liver | C7B.02 | Secondary carcinoid tumors of liver |
209.73 | Secondary neuroendocrine tumor of bone | C7B.03 | Secondary carcinoid tumors of bone |
209.74 | Secondary neuroendocrine tumor of peritoneum | C7B.04 | Secondary carcinoid tumors of peritoneum |
209.79 | Secondary neuroendocrine tumor of other sites | C7B.09 C7B.8 | Secondary carcinoid tumors of other sites Other secondary neuroendocrine tumors |
211.1 - 211.9 | Benign neoplasm of other parts of the digestive system | D12.0 - D12.9 | Benign neoplasm of colon, rectum, anus and anal canal |
D13.0 - D13.99 | Benign neoplasm of other and ill-defined parts of digestive system | ||
D19.1 | Benign neoplasm of mesothelial tissue of peritoneum | ||
D20.0 - D20.1 | Benign neoplasm of soft tissue of retroperitoneum and peritoneum | ||
K31.7 | Polyp of stomach and duodenum | ||
K63.5 | Polyp of colon | ||
213.6 | Benign neoplasm of pelvic bones, sacrum, and coccyx | D16.8 | Benign neoplasm of pelvic bones, sacrum and coccyx |
213.9 | Benign neoplasm of bone and articular cartilage, site unspecified | D16.9 | Benign neoplasm of bone and articular cartilage, unspecified |
214.3 | Lipoma of intra-abdominal organs | D17.5 D17.71 | Benign lipomatous neoplasm of intra-abdominal organs Benign lipomatous neoplasm of kidney |
215.5 | Other benign neoplasm of connective and other soft tissue of abdomen | D21.4 | Benign neoplasm of connective and other soft tissue of abdomen |
215.6 | Other benign neoplasm of connective and other soft tissue of pelvis | D21.5 | Benign neoplasm of connective and other soft tissue of pelvis |
218.0 | Submucous leiomyoma of uterus | D25.0 | Submucous leiomyoma of uterus |
218.1 | Intramural leiomyoma of uterus | D25.1 | Intramural leiomyoma of uterus |
218.2 | Subserous leiomyoma of uterus | D25.2 | Subserosal leiomyoma of uterus |
218.9 | Leiomyoma of uterus, unspecified | D25.9 | Leiomyoma of uterus, unspecified |
219.0 - 219.9 | Other benign neoplasm of uterus | D26.0 - D26.9 | Other benign neoplasms of uterus |
220 | Benign neoplasm of ovary | D27.0 - D27.9 | Benign neoplasm of ovary |
221.0 - 221.9 | Benign neoplasm of other female genital organs | D28.0 - D28.9 | Benign neoplasm of other and unspecified female genital organs |
222.0 - 222.9 | Benign neoplasm of male genital organs | D29.0 - D29.9 | Benign neoplasm of male genital organs |
223.0 - 223.9 | Benign neoplasm of kidney and other urinary organs | D30.00 - D30.9 | Benign neoplasm of urinary organs |
227.0 | Benign neoplasm of adrenal gland | D35.01 D35.02 | Benign neoplasm of right adrenal gland Benign neoplasm of left adrenal gland |
230.2 | Carcinoma in situ of stomach | D00.2 | Carcinoma in situ of stomach |
230.3 | Carcinoma in situ of colon | D01.0 | Carcinoma in situ of colon |
230.4 | Carcinoma in situ of rectum | D01.1 D01.2 | Carcinoma in situ of rectosigmoid junction Carcinoma in situ of rectum |
230.5 | Carcinoma in situ of anal canal | D01.3 | Carcinoma in situ of anus and anal canal |
230.6 | Carcinoma in situ of anus, unspecified | D01.3 | Carcinoma in situ of anus and anal canal |
230.7 | Carcinoma in situ of other and unspecified parts of intestine | D01.40 D01.49 | Carcinoma in situ of unspecified part of intestine Carcinoma in situ of other parts of intestine |
230.8 | Carcinoma in situ of liver and biliary system | D01.5 | Carcinoma in situ of liver, gallbladder and bile ducts |
233.1 | Carcinoma in situ of cervix uteri | D06.0 - D06.9 | Carcinoma in situ of cervix uteri |
233.2 | Carcinoma in situ of other and unspecified parts of uterus | D07.0 | Carcinoma in situ of endometrium |
233.30 - 233.39 | Other and unspecified female genital organs | D07.1 | Carcinoma in situ of vulva |
D07.2 | Carcinoma in situ of vagina | ||
D07.30 - D07.39 | Carcinoma in situ of other and unspecified female genital organs | ||
233.4 | Carcinoma in situ of prostate | D07.5 | Carcinoma in situ of prostate |
233.5 | Carcinoma in situ of penis | D07.4 | Carcinoma in situ of penis |
233.6 | Carcinoma in situ of other and unspecified male genital organs | D07.60 - D07.69 | Carcinoma in situ of other and unspecified male genital organs |
233.7 | Carcinoma in situ of bladder | D09.0 | Carcinoma in situ of bladder |
233.9 | Carcinoma in situ of other and unspecified urinary organs | D09.10 D09.19 | Carcinoma in situ of unspecified urinary organ Carcinoma in situ of other urinary organs |
235.2 | Neoplasm of uncertain behavior of stomach, intestines, and rectum | D37.1 | Neoplasm of uncertain behavior of stomach |
D37.2 | Neoplasm of uncertain behavior of small intestine | ||
D37.3 | Neoplasm of uncertain behavior of appendix | ||
D37.4 | Neoplasm of uncertain behavior of colon | ||
D37.5 | Neoplasm of uncertain behavior of rectum | ||
235.3 | Neoplasm of uncertain behavior of liver and biliary passages | D37.6 | Neoplasm of uncertain behavior of liver, gallbladder and bile ducts |
235.4 | Neoplasm of uncertain behavior of retroperitoneum and peritoneum | D48.3 D48.4 | Neoplasm of uncertain behavior of retroperitoneum Neoplasm of uncertain behavior of peritoneum |
235.5 | Neoplasm of uncertain behavior of other and unspecified digestive organs | D37.8 D37.9 | Neoplasm of uncertain behavior of other specified digestive organs Neoplasm of uncertain behavior of digestive organ, unspecified |
236.0 | Neoplasm of uncertain behavior of uterus | D39.0 | Neoplasm of uncertain behavior of uterus |
236.2 | Neoplasm of uncertain behavior of ovary | D39.10 - D39.12 | Neoplasm of uncertain behavior of ovary |
236.3 | Neoplasm of uncertain behavior of other and unspecified female genital organs | D39.8 D39.9 | Neoplasm of uncertain behavior of other specified female genital organs Neoplasm of uncertain behavior of female genital organ, unspecified |
236.4 | Neoplasm of uncertain behavior of testis | D40.10 - D40.12 | Neoplasm of uncertain behavior of testis |
236.5 | Neoplasm of uncertain behavior of prostate | D40.0 | Neoplasm of uncertain behavior of prostate |
236.6 | Neoplasm of uncertain behavior of other and unspecified male genital organs | D40.8 D40.9 | Neoplasm of uncertain behavior of other specified male genital organs Neoplasm of uncertain behavior of male genital organ, unspecified |
236.7 | Neoplasm of uncertain behavior of bladder | D41.4 | Neoplasm of uncertain behavior of bladder |
236.90 | Neoplasm of uncertain behavior of urinary organ, unspecified | D41.9 | Neoplasm of uncertain behavior of unspecified urinary organ |
236.91 | Neoplasm of uncertain behavior of kidney and ureter | D41.00 - D41.02 | Neoplasm of uncertain behavior of kidney |
D41.10 - D41.12 | Neoplasm of uncertain behavior of renal pelvis | ||
D41.20 - D41.22 | Neoplasm of uncertain behavior of ureter | ||
236.99 | Neoplasm of uncertain behavior of other and unspecified urinary organs | D41.3 D41.8 | Neoplasm of uncertain behavior of urethra Neoplasm of uncertain behavior of other specified urinary organs |
237.2 | Neoplasm of uncertain behavior of adrenal gland | D44.10 - D44.12 | Neoplasm of uncertain behavior of adrenal gland |
D48.113 | Desmoid tumor of abdominal wall | ||
D48.114 | Desmoid tumor, intraabdominal | ||
238.8 | Neoplasm of unspecified nature of other genitourinary organs | D48.7 | Neoplasm of uncertain behavior of other specified sites |
239.4 | Neoplasm of unspecified nature of bladder | D49.4 | Neoplasm of unspecified behavior of bladder |
239.5 | Neoplasm of unspecified nature of other genitourinary organs | D49.512 | Neoplasm of unspecified behavior of left kidney |
D49.519 | Neoplasm of unspecified behavior of unspecified kidney | ||
D49.59 | Neoplasm unspecified behavior of other genitourinary organ | ||
441.02 | Dissecting aortic aneurysm (any part), abdominal | I71.02 | Dissection of abdominal aorta |
441.03 | Dissecting aortic aneurysm (any part), thoracoabdominal | I71.03 | Dissection of thoracoabdominal aorta |
441.3 | Abdominal aneurysm, ruptured | I71.30, I71.31, I71.32, I71.33 | Abdominal aortic aneurysm, ruptured |
441.4 | Abdominal aneurysm without mention of rupture | I71.40, I71.41, I71.42, I71.43 | Abdominal aortic aneurysm, without rupture |
441.6 | Thoracoabdominal aneurysm, ruptured | I71.50, I71.51, I71.52 | Thoracoabdominal aortic aneurysm, ruptured |
441.7 | Thoracoabdominal aneurysm without mention of rupture | I71.60, I71.61, I71.62 | Thoracoabdominal aortic aneurysm, without rupture |
I72.5 | Aneurysm of other precerebral arteries | ||
I72.6 | Aneurysm of vertebral artery | ||
442.84 442.89 | Aneurysm of other visceral artery Aneurysm of other specified artery | I72.8 | Aneurysm of other specified arteries |
555.0 - 555.9 | Regional enteritis (Crohn's Disease) | K50.00 - K50.919 | Crohn's disease [regional enteritis] |
567.22 | Peritoneal abscess | K65.1 | Peritoneal abscess |
567.31 | Psoas muscle abscess | K68.12 | Psoas muscle abscess |
567.38 | Other retroperitoneal abscess | K68.19 | Other retroperitoneal abscess |
569.5 | Abscess of intestine | K63.0 | Abscess of intestine |
571.0 - 571.9 | Chronic liver disease and cirrhosis | K70.0 - K70.9 | Alcoholic liver disease |
K73.0 - K73.9 | Chronic hepatitis, not elsewhere classified | ||
K74.00 - K74.69 | Fibrosis and cirrhosis of liver | ||
K75.4 | Autoimmune hepatitis | ||
K75.81 | Nonalcoholic steatohepatitis (NASH) | ||
K76.0 | Fatty (change of) liver, not elsewhere classified | ||
K76.9 | Liver disease, unspecified | ||
572.0 | Abscess of liver | K75.0 | Abscess of liver |
574.0 - 574.91 | Cholelithiasis | K80.00 - K80.81 | Cholelithiasis |
577.0 - 577.9 | Diseases of pancreas | B25.2 | Cytomegaloviral pancreatitis |
K85.00 - K85.92 | Acute pancreatitis | ||
K86.0 - K86.9 | Other diseases of pancreas | ||
K87 | Disorders of gallbladder, biliary tract and pancreas in diseases classified elsewhere | ||
590.2 | Renal and perinephric abscess | N15.1 | Renal and perinephric abscess |
593.2 | Acquired cyst of kidney | N28.1 | Cyst of kidney, acquired |
N28.89 | Other specified disorders of kidney and ureter | ||
593.9 | Unspecified disorder of kidney and ureter | N28.9 | Disorder of kidney and ureter, unspecified |
599.2 | Urethral diverticulum | N36.1 | Urethral diverticulum |
599.84 | Other specified disorders of urethra | N36.8 | Other specified disorders of urethra |
608.83 | Obstetrical pelvic hematoma | N50.1 | Vascular disorders of male genital organs |
N80.00, N80.01, N80.02, N80.03 | Endometriosis of uterus | ||
N80.101, N80.102, N80.103, N80.109 | Endometriosis of ovary, unspecified depth | ||
N80.111, N80.112, N80.113, N80.119 | Superficial endometriosis of the ovary | ||
N80.121, N80.122, N80.123, N80.129 | Deep endometriosis of ovary | ||
N80.201, N80.202, N80.203, N80.209 | Endometriosis of fallopian tube, unspecified depth | ||
N80.211, N80.212, N80.213, N80.219 | Superficial endometriosis of fallopian tube | ||
N80.221, N80.222, N80.223, N80.229 | Deep endometriosis of the fallopian tube | ||
N80.30 | Endometriosis of pelvic peritoneum, unspecified | ||
N80.311, N80.312, N80.319 | Endometriosis of the anterior cul-de-sac | ||
N80.321, N80.322, N80.329 | Endometriosis of the posterior cul-de-sac | ||
N80.331, N80.332, N80.333, N80.339 | Superficial endometriosis of the pelvic sidewall | ||
N80.341, N80.342, N80.343, N80.349 | Deep endometriosis of the pelvic sidewall | ||
N80.351, N80.352, N80.353, N80.359 | Endometriosis of the pelvic sidewall, unspecified depth | ||
N80.361, N80.362, N80.363, N80.369 | Superficial endometriosis of the pelvic brim | ||
N80.371, N80.372, N80.373, N80.379 | Deep endometriosis of the pelvic brim | ||
N80.381, N80.382, N80.383, N80.389 | Endometriosis of the pelvic brim, unspecified depth | ||
N80.391, N80.392, N80.399 | Endometriosis of other pelvic peritoneum | ||
N80.3A1, N80.3A2, N80.3A3, N80.3A9 | Superficial endometriosis of the uterosacral ligament(s) | ||
N80.3B1, N80.3B2, N80.3B3, N80.3B9 | Deep endometriosis of the uterosacral ligament(s) | ||
N80.3C1, N80.3C2, N80.3C3, N80.3C9 | Endometriosis of the uterosacral ligament(s), unspecified depth | ||
N80.40, N80.41, N80.42 | Endometriosis of rectovaginal septum and vagina | ||
N80.50 | Endometriosis of intestine, unspecified | ||
N80.511, N80.512, N80.519 | Endometriosis of the rectum | ||
N80.521, N80.522, N80.529 | Endometriosis of the sigmoid colon | ||
N80.531, N80.532, N80.539 | Endometriosis of the cecum | ||
N80.541, N80.542, N80.549 | Endometriosis of the appendix | ||
N80.551, N80.552, N80.559 | Endometriosis of other parts of the colon | ||
N80.561, N80.562, N80.569 | Endometriosis of the small intestine | ||
N80.6 | Endometriosis in cutaneous scar | ||
N80.A0, N80.A1, N80.A2 | Endometriosis of bladder | ||
N80.A41, N80.A42, N80.A43, N80.A49 | Superficial endometriosis of ureter | ||
N80.A51, N80.A52, N80.A53, N80.A59 | Deep endometriosis of ureter | ||
N80.A61, N80.A62, N80.A63, N80.A69 | Endometriosis of ureter, unspecified depth | ||
N80.B1 | Endometriosis of pleura | ||
N80.B2 | Endometriosis of lung | ||
N80.B31, N80.B32, N80.B39 | Endometriosis of diaphragm | ||
N80.B4 | Endometriosis of the pericardial space | ||
N80.B5 | Endometriosis of the mediastinal space | ||
N80.B6 | Endometriosis of cardiothoracic space | ||
N80.C0 | Endometriosis of the abdomen, unspecified | ||
N80.C10, N80.C11, N80.C19 | Endometriosis of the anterior abdominal wall | ||
N80.C2 | Endometriosis of the umbilicus | ||
N80.C3 | Endometriosis of the inguinal canal | ||
N80.C4 | Endometriosis of extra-pelvic abdominal peritoneum | ||
N80.C9 | Endometriosis of other site of abdomen | ||
N80.D0, N80.D1, N80.D2, N80.D3, N80.D4, N80.D5, N80.D6, N80.D9 | Endometriosis of the pelvic nerves | ||
N80.8 | Other endometriosis | ||
617.0 - 617.9 | Endometriosis Range | N80.9 | Endometriosis unspecified |
618.0 - 618.9 | Genital prolapse Range | N81.0 - N81.9 N99.3 | Female genital prolapsed Prolapse of vaginal vault after hysterectomy |
620.8 | Other noninflammatory disorder of ovary, fallopian tube, and broad ligament | N83.6 | Hematosalpinx |
N83.8 | Other noninflammatory disorders of ovary, fallopian tube and broad ligament | ||
N99.83 | Residual ovary syndrome | ||
626.0 | Absence of menstruation | N91.0 | Primary amenorrhea |
N91.1 | Secondary amenorrhea | ||
N91.2 | Amenorrhea, unspecified | ||
627.1 | Postmenopausal bleeding | N95.0 | Postmenopausal bleeding |
654.10 - 654.14 | Tumors of body of pregnant uterus range | O34.10 - O34.13 | Maternal care for benign tumor of corpus uteri |
O35.AXX0, O35.AXX1, O35.AXX2, O35.AXX3, O35.AXX4, O35.AXX5, O35.AXX9 | Maternal care for other (suspected) fetal abnormality and damage, fetal facial anomalies | ||
O35.BXX0, O35.BXX1, O35.BXX2, O35.BXX3, O35.BXX4, O35.BXX5, O35.BXX9 | Maternal care for other (suspected) fetal abnormality and damage, fetal cardiac anomalies | ||
O35.CXX0, O35.CXX1, O35.CXX2, O35.CXX3, O35.CXX4, O35.CXX5, O35.CXX9 | Maternal care for other (suspected) fetal abnormality and damage, fetal pulmonary anomalies | ||
O35.DXX0, O35.DXX1, O35.DXX2, O35.DXX3, O35.DXX4, O35.DXX5, O35.DXX9 | Maternal care for other (suspected) fetal abnormality and damage, fetal gastrointestinal anomalies | ||
O35.EXX0, O35.EXX1, O35.EXX2, O35.EXX3, O35.EXX4, O35.EXX5, O35.EXX9 | Maternal care for other (suspected) fetal abnormality and damage, fetal genitourinary anomalies | ||
O35.FXX0, O35.FXX1, O35.FXX2, O35.FXX3, O35.FXX4, O35.FXX5, O35.FXX9 | Maternal care for other (suspected) fetal abnormality and damage, fetal musculoskeletal anomalies of trunk | ||
O35.GXX0, O35.GXX1, O35.GXX2, O35.GXX3, O35.GXX4, O35.GXX5, O35.GXX9 | Maternal care for other (suspected) fetal abnormality and damage, fetal upper extremities anomalies | ||
O35.HXX0, O35.HXX1, O35.HXX2, O35.HXX3, O35.HXX4, O35.HXX5, O35.HXX9 | Maternal care for other (suspected) fetal abnormality and damage, fetal lower extremities anomalies | ||
655.80 - 655.83 | Other known or suspected fetal abnormality, not elsewhere classified, affecting management of mother range | O35.8XX0 - O35.8XX9 | Maternal care for other (suspected) fetal abnormality and damage |
665.70-665.74 | Obstetrical pelvic hematoma range | O71.7 | Obstetric hematoma of pelvis |
719.45 | Pain in joint, pelvic region and thigh | M25.551 - M25.559 | Pain in hip |
M80.0B1A, M80.0B1D, M80.0B1G, M80.0B1K, M80.0B1P, M80.0B1S | Age-related osteoporosis with current pathological fracture, right pelvis | ||
M80.0B2A, M80.0B2D, M80.0B2G, M80.0B2K, M80.0B2P, M80.0B2S | Age-related osteoporosis with current pathological fracture, left pelvis | ||
M80.0B9A, M80.0B9D, M80.0B9G, M80.0B9K, M80.0B9P, M80.0B9S | Age-related osteoporosis with current pathological fracture, unspecified pelvis | ||
M80.8B1A, M80.8B1D, M80.8B1G, M80.8B1K, M80.8B1P, M80.8B1S | Other osteoporosis with current pathological fracture, right pelvis | ||
M80.8B2A, M80.8B2D, M80.8B2G, M80.8B2K, M80.8B2P, M80.8B2S | Other osteoporosis with current pathological fracture, left pelvis | ||
M80.8B9A, M80.8B9D, M80.8B9G, M80.8B9K, M80.8B9P, M80.8B9S | Other osteoporosis with current pathological fracture, unspecified pelvis | ||
732.1 | Follow-up examination following other surgery | M91.0 - M91.92 | Juvenile osteochondrosis of hip and pelvis |
733.42 | Aseptic necrosis of head and neck of femur | M87.051 | Idiopathic aseptic necrosis of right femur |
M87.052 | Idiopathic aseptic necrosis of left femur | ||
M87.150 - M87.159 | Osteonecrosis due to drugs, pelvis and femur | ||
M87.251 | Osteonecrosis due to previous trauma, right femur | ||
M87.252 | Osteonecrosis due to previous trauma, left femur | ||
M87.350 - M87.353 | Other secondary osteonecrosis, pelvis and femur | ||
M87.850 - M87.859 | Other osteonecrosis, pelvis and femur | ||
M90.551 - M90.552 | Osteonecrosis in diseases classified elsewhere, thigh | ||
733.43 | Aseptic necrosis of medial femoral condyle | M87.051 | Idiopathic aseptic necrosis of right femur |
M87.052 | Idiopathic aseptic necrosis of left femur | ||
M87.150 - M87.159 | Osteonecrosis due to drugs, pelvis and femur | ||
M87.251 | Osteonecrosis due to previous trauma, right femur | ||
M87.252 | Osteonecrosis due to previous trauma, left femur | ||
M87.350 - M87.353 | Other secondary osteonecrosis, pelvis and femur | ||
M87.851 | Other osteonecrosis, right femur | ||
M87.852 | Other osteonecrosis, left femur | ||
747.61 | Congenital gastrointestinal vessel anomaly | Q26.5 | Anomalous portal venous connection |
Q26.6 | Portal vein-hepatic artery fistula | ||
Q27.33 | Arteriovenous malformation of digestive system vessel | ||
747.62 | Congenital renal vessel anomaly | Q27.1 | Congenital renal artery stenosis |
Q27.2 | Other congenital malformations of renal artery | ||
Q27.34 | Arteriovenous malformation of renal vessel | ||
751.5 | Other congenital anomalies of intestine | Q43.4 | Duplication of intestine |
Q43.5 | Ectopic anus | ||
Q43.6 | Congenital fistula of rectum and anus | ||
Q43.7 | Persistent cloaca | ||
Q43.8 | Other specified congenital malformations of intestine | ||
751.60 | Unspecified congenital anomaly of gallbladder, bile ducts, and liver | Q44.1 | Other congenital malformations of gallbladder |
Q44.5 | Other congenital malformations of bile ducts | ||
751.69 | Other congenital anomaly of gallbladder, bile ducts, and liver | Q44.0 | Agenesis, aplasia and hypoplasia of gallbladder |
Q44.1 | Other congenital malformations of gallbladder | ||
Q44.4 | Choledochal cyst | ||
Q44.5 | Other congenital malformations of bile ducts | ||
Q44.70 | Other congenital malformation of liver, unspecified | ||
Q44.71 | Alagille syndrome | ||
Q44.79 | Other congenital malformations of liver | ||
751.7 | Congenital anomalies of pancreas | Q45.0 | Agenesis, aplasia and hypoplasia of pancreas |
Q45.1 | Annular pancreas | ||
Q45.2 | Congenital pancreatic cyst | ||
Q45.3 | Other congenital malformations of pancreas and pancreatic duct | ||
752.39 | Other anomalies of uterus | Q51.818 Q51.9 | Other congenital malformations of uterus Congenital malformation of uterus and cervix, unspecified |
752.51 | Undescended testis | Q53.00 - Q53.9 | Undescended and ectopic testicle |
753.11 | Congenital single renal cyst | Q61.01 | Congenital single renal cyst |
Q61.2 | Polycystic kidney, adult type | ||
759.0 | Congenital anomalies of spleen | Q89.01 Q89.09 | Asplenia (congenital) Congenital malformations of spleen |
759.1 | Congenital anomalies of adrenal gland | Q89.1 | Congenital malformations of adrenal gland |
789.00-789.09 | Abdominal pain | R10.0 | Acute abdomen |
R10.11 | Right upper quadrant pain | ||
R10.12 | Left upper quadrant pain | ||
R10.13 | Epigastric pain | ||
R10.31 | Right lower quadrant pain | ||
R10.32 | Left lower quadrant pain | ||
R10.33 | Periumbilical pain | ||
R10.84 | Generalized abdominal pain | ||
R10.85 | Abdominal pain of multiple sites (New 10/01/2025) | ||
R10.8A1, R10.8A2, R10.8A3, R10.8A9 | Flank tenderness (New 10/01/2025) | ||
R10.A0, R10.A1, R10.A2, R10.A3 | Pain localized to flank (New 10/01/2025) | ||
R16.0 | Hepatomegaly, not elsewhere classified | ||
789.30 -789.39 | Abdominal or pelvic swelling, mass, or lump | R19.00 - R19.09 | Intra-abdominal and pelvic swelling, mass and lump |
790.93 | Elevated prostate specific antigen (PSA) | R97.20 | Elevated prostate specific antigen [PSA] |
R97.21 | Rising PSA following treatment for malignant neoplasm of prostate | ||
793.3 | Nonspecific (abnormal) findings on radiological and other examination of biliary tract | R93.2 | Abnormal findings on diagnostic imaging of liver and biliary tract |
793.4 | Nonspecific (abnormal) findings on radiological and other examination of gastrointestinal tract | R93.3 | Abnormal findings on diagnostic imaging of other parts of digestive tract |
793.5 | Nonspecific (abnormal) findings on radiological and other examination of genitourinary organs | R93.41 | Abnormal radiologic findings on diagnostic imaging of renal pelvis, ureter, or bladder |
R93.421 | Abnormal radiologic findings on diagnostic imaging of right kidney | ||
R93.422 | Abnormal radiologic findings on diagnostic imaging of left kidney | ||
R93.429 | Abnormal radiologic findings on diagnostic imaging of unspecified kidney | ||
R93.49 | Abnormal radiologic findings on diagnostic imaging of other urinary organs | ||
793.6 | Nonspecific (abnormal) findings on radiological and other examination of abdominal area, including retroperitoneum | R93.5 | Abnormal findings on diagnostic imaging of other abdominal regions, including retroperitoneum |
793.99 | Other nonspecific (abnormal) findings on radiological and other examination of body structure | R90.89 | Other abnormal findings on diagnostic imaging of central nervous system |
R93.811, R93.812, R93.813, R93.819 | Abnormal radiologic findings on diagnostic imaging of testis | ||
R93.89 | Abnormal findings on diagnostic imaging of other specified body structures | ||
794.4 | Nonspecific abnormal results of kidney function study | R94.4 | Abnormal results of kidney function studies |
794.6 | Nonspecific abnormal results of other endocrine function study | R94.7 | Abnormal results of other endocrine function studies |
794.8 | Nonspecific abnormal results of liver function study | R94.5 | Abnormal results of liver function studies |
808.0 - 808.9 | Fracture of pelvis | S32.301A - S32.399S | Fracture of ilium |
S32.401A - S32.499S | Fracture of acetabulum | ||
S32.501A - S32.599S | Fracture of pubis | ||
S32.601A - S32.699S | Fracture of ischium | ||
S32.810A - S32.89X | Fracture of other parts of pelvis | ||
S32.9XXA - S32.9XXS | Fracture of unspecified parts of lumbosacral spine and pelvis | ||
820.00 - 820.9 | Fracture of neck of femur | S72.001A - S72.099S | Fracture of head and neck of femur |
S72.101A - S72.146S | Pertrochanteric fracture | ||
S72.21XA - S72.26XS | Subtrochanteric fracture of femur | ||
S79.001A - S79.009S | Physeal fracture of upper end of femur | ||
S79.011A - S79.019S | Salter-Harris Type I physeal fracture of upper end of femur | ||
S79.091A - S79.099S | Other physeal fracture of upper end of femur | ||
840.7 | Superior glenoid labrum lesion | S43.431A - S43.439S | Superior glenoid labrum lesion |
867.0 | Injury to other specified pelvic organs without mention of open wound into cavity | S37.20XA - S37.29XS S37.30XA - S37.39XS | Injury of bladder Injury of urethra |
V10.00 | Personal history of malignant neoplasm of unspecified site in gastrointestinal tract | Z85.00 | Personal history of malignant neoplasm of unspecified digestive organ |
V10.04 | Personal history of malignant neoplasm of stomach | Z85.028 | Personal history of other malignant neoplasm of stomach |
V10.05 | Personal history of malignant neoplasm of large intestine | Z85.038 | Personal history of other malignant neoplasm of large intestine |
V10.07 | Personal history of malignant neoplasm of liver | Z85.05 | Personal history of malignant neoplasm of liver |
V10.09 | Personal history of malignant neoplasm of other site in gastrointestinal tract | Z85.068 | Personal history of other malignant neoplasm of small intestine |
Z85.07 | Personal history of malignant neoplasm of pancreas | ||
Z85.09 | Personal history of malignant neoplasm of other digestive organs | ||
V10.40-V10.49 | Personal history of malignant neoplasm of genital organs range | Z85.40 - Z85.49 | Personal history of malignant neoplasm of genital organs |
V10.52 | Personal history of malignant neoplasm of kidney | Z85.528 | Personal history of other malignant neoplasm of kidney |
V10.90 | Personal history of unspecified malignant neoplasm | Z85.9 | Personal history of malignant neoplasm, unspecified |
V10.91 | Personal history of malignant neuroendocrine tumor | Z85.020 | Personal history of malignant carcinoid tumor of stomach |
Z85.030 | Personal history of malignant carcinoid tumor of large intestine | ||
Z85.040 | Personal history of malignant carcinoid tumor of rectum | ||
Z85.060 | Personal history of malignant carcinoid tumor of small intestine | ||
Z85.110 | Personal history of malignant carcinoid tumor of bronchus and lung | ||
Z85.230 | Personal history of malignant carcinoid tumor of thymus | ||
Z85.520 | Personal history of malignant carcinoid tumor of kidney | ||
Z85.821 | Personal history of Merkel cell carcinoma | ||
V15.08 | Personal history of allergy to radiographic dye | Z91.041 | Radiographic dye allergy status |
V15.29 | Personal history of surgery to other organs | Z98.890 | Other specified postprocedural states |
Z98.891 | History of uterine scar from previous surgery | ||
V29.8 | Observation and evaluation of newborns and infants for other specified suspected condition not found | P00.89 | Newborn affected by other maternal conditions |
V42.0 | Kidney replaced by transplant | Z48.22 Z94.0 | Encounter for aftercare following kidney transplant Kidney transplant status |
V42.83 | Pancreas replaced by transplant | Z94.83 | Pancreas transplant status |
V43.64 | Hip joint replacement by other means | Z96.641 - Z96.649 | Presence of artificial hip joint |
V58.42 | Aftercare following surgery for neoplasm | Z48.3 | Aftercare following surgery for neoplasm |
V59.6 | Liver donor | Z52.6 | Liver donor |
V67.09 | Follow-up examination, following other surgery | Z09 | Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm |
V67.1 V67.2 V67.9 | Radiotherapy follow-up examination Chemotherapy follow-up examination Unspecified follow-up examination | Z08 Z09 | Encounter for follow-up examination after completed treatment for malignant neoplasm Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm |
V71.1 | Observation for suspected malignant neoplasm | Z03.89 | Encounter for observation for other suspected diseases and conditions ruled out |
V71.89 | Observation for other specified suspected conditions | Z03.6 Z03.89 | Encounter for observation for suspected toxic effect from ingested substance ruled out Encounter for observation for other suspected diseases and conditions ruled out |
V72.83 | Other specified preoperative examination | Z01.818 | Encounter for other preprocedural examination |
V76.50 - V76.52 | Special screening for malignant neoplasms of the intestine | Z12.10 | Encounter for screening for malignant neoplasm of intestinal tract, unspecified |
Z12.11 | Encounter for screening for malignant neoplasm of colon | ||
Z12.13 | Encounter for screening for malignant neoplasm of small intestine | ||
V84.09 | Genetic susceptibility to other malignant neoplasm | Z15.09 | Genetic susceptibility to other malignant neoplasm |
CPT copyright American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.